Pretargeted imaging and therapy

Mohamed Altai, Rosemery Membreno, Brendon Cook, Vladimir Tolmachev, Brian M. Zeglis

Research output: Contribution to journalArticlepeer-review

56 Citations (Scopus)


In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors. In this short review, we seek to provide a brief yet informative survey of the 4 preeminent mechanistic approaches to pretargeting, strategies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, and bioorthogonal click chemistry.

Original languageEnglish
Pages (from-to)1553-1559
Number of pages7
JournalJournal of Nuclear Medicine
Issue number10
Publication statusPublished - 1 Oct 2017
Externally publishedYes


  • Biotin
  • Bispecific antibody
  • Click chemistry
  • Multistep targeting
  • Pretargeting
  • Streptavidin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Pretargeted imaging and therapy'. Together they form a unique fingerprint.

Cite this